Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS

Table 4 SYN-1, S1P and VE-cadherin concentrations over time in 375 patients and by ALBIOS treatment

	ALBIOS patients			p value*
	Total (375)	Albumin (188)	Crystalloids (187)	p value*
SYN-1 (ng/mL)
Day 1	185 [90–381]	176 [86–381]	184 [94–385]	0.41
Day 2	420 [239–962]	400 [228–954]	422 [247–984]	0.29
Day 7	481 [264–960]	469 [255–904]	502 [289–1000]	0.37
Mixed model analysis**		P time		7.6 × 10^–80
		P treatment		0.253
		P interaction time*treatment		0.883
S1P (ng/mL)
Day 1	86.5 [63.7–120.0]	87.6 [62.8–123.7]	84.2 [64.0–118.8]	0.91
Day 2	87.2 [67.6–122.1]	90.0 [66.9–128.5]	86.2 [67.7–117.2]	0.35
Day 7	91.6 [69.9–132.9]	93.0 [70.6–138.9]	89.9 [68.0–127.9]	0.29
Mixed model analysis**		P time		0.001
		P treatment		0.147
		P interaction time*treatment		0.717
VE-cadherin (ng/mL)
Day 1	1697 [1313–2199]	1636 [1270–2068]	1737 [1394–2317]	0.004
Day 2	1751 [1433–2310]	1662 [1381–2144]	1837 [1475–2398]	0.009
Day 7	1869 [1523–2332]	1781 [1494–2251]	1976 [1618–2395]	0.02
Mixed model analysis**		P time		4.5 × 10^–13
		P treatment		0.003
		P interaction time*treatment		0.193

All biomarker concentrations are reported as median [IQR]
SYN-1, syndecan-1; S1P, sphingosine 1-phosphate; IQR, interquartile range;
*p value for Mann–Whitney to compare ALBIOS-Albumin vs ALBIOS-crystalloids
**p value for mixed model analysis including biomarker value at three time points and treatment. A Greenhouse–Geisser correction was included to correct for sphericity

ISSN: 1364-8535